NIKKEI 225
27,767.07 -232.89 (-0.83%) HANG SENG
19,593.07 -410.37 (-2.05%) CRUDE OIL
90.14 -0.36 (-0.40%) GOLD FUTURES
1,792.40 -1.60 (-0.09%) DOW
32,774.41 -58.09 (-0.18%) BTC-GBP
18,960.53 -858.00 (-4.33%)
CVAC Oct 2022 20.000 put
| Previous close | 8.00 |
| Open | 8.00 |
| Bid | 6.70 |
| Ask | 8.20 |
| Strike | 20.00 |
| Expiry date | 2022-10-21 |
| Day's range | 8.00 - 8.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 177 |
- Reuters
BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims
COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac. The lawsuit, filed Monday, said CureVac is trying to profit from the success of BioNTech and Pfizer's COVID-19 vaccines after CureVac's efforts to create its own vaccine failed.
- Zacks
Wall Street Analysts Predict a 96% Upside in CureVac N.V. (CVAC): Here's What You Should Know
The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 96.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Simply Wall St.
Analysts Expect Breakeven For CureVac N.V. (NASDAQ:CVAC) Before Long
We feel now is a pretty good time to analyse CureVac N.V.'s ( NASDAQ:CVAC ) business as it appears the company may be...
